Carolyn Cross is the Founder, Chairman and Chief Executive Officer of Ondine Biomedical Inc., a Vancouver based MedTech company whose mission is to save lives and reduce suffering of millions of people by developing effective non-antibiotic treatment and prevention therapies for a broad-spectrum of multidrug-resistant bacterial, viral and fungal infections. Ondine's antimicrobial program utilizes a platform technology called Photodisinfection, a light-activated approach for use in humans being developed to provide rapid antimicrobial efficacy without elevating risk of resistance. Ondine’s life-saving and award-winning nasal Photodisinfection is already helping leading Canadian hospitals reduce surgical site infections by nearly 80%. In six minutes of treatment, it eradicates infection-causing pathogens--including drug-resistant bacteria (i.e. MRSA, MSSA), viruses, and fungi (i.e. aspergillus, Candida auris)--that reside in the human nose and are easily transmitted from there to wounds, surgical sites, hospital surfaces, and other patients. In addition to Ondine’s nasal Photodisinfection therapy, other applications of the Photodisinfection platform are under development, including treatment of chronic rhinosinusitis, treatment of burns and wounds, and disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia.